These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 21391238)
1. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Hottinger AF; Iwamoto FM; Karimi S; Riedel E; Dantis J; Park J; Panageas KS; Lassman AB; Abrey LE; Fleisher M; Holland EC; DeAngelis LM; Hormigo A Ann Neurol; 2011 Jul; 70(1):163-9. PubMed ID: 21391238 [TBL] [Abstract][Full Text] [Related]
2. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973 [TBL] [Abstract][Full Text] [Related]
3. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900 [TBL] [Abstract][Full Text] [Related]
4. Serum markers in early-stage and locally advanced melanoma. Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577 [TBL] [Abstract][Full Text] [Related]
5. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Biggar RJ; Johansen JS; Smedby KE; Rostgaard K; Chang ET; Adami HO; Glimelius B; Molin D; Hamilton-Dutoit S; Melbye M; Hjalgrim H Clin Cancer Res; 2008 Nov; 14(21):6974-8. PubMed ID: 18980992 [TBL] [Abstract][Full Text] [Related]
6. YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndrome. Kastelijn EA; van Moorsel CH; Ruven HJ; Korthagen NM; Kwakkel-van Erp JM; van de Graaf EA; Zanen P; van Kessel DA; Grutters JC Sarcoidosis Vasc Diffuse Lung Dis; 2013 Mar; 30(1):28-35. PubMed ID: 24003532 [TBL] [Abstract][Full Text] [Related]
7. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Coskun U; Yamac D; Gulbahar O; Sancak B; Karaman N; Ozkan S Neoplasma; 2007; 54(4):348-52. PubMed ID: 17845129 [TBL] [Abstract][Full Text] [Related]
8. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029 [TBL] [Abstract][Full Text] [Related]
9. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295 [TBL] [Abstract][Full Text] [Related]
10. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034 [TBL] [Abstract][Full Text] [Related]
11. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116 [TBL] [Abstract][Full Text] [Related]
12. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215 [TBL] [Abstract][Full Text] [Related]
13. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595 [TBL] [Abstract][Full Text] [Related]
14. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792 [TBL] [Abstract][Full Text] [Related]
15. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Pedersen SJ; Hetland ML; Sørensen IJ; Ostergaard M; Nielsen HJ; Johansen JS Clin Rheumatol; 2010 Nov; 29(11):1301-9. PubMed ID: 20640910 [TBL] [Abstract][Full Text] [Related]
17. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447 [TBL] [Abstract][Full Text] [Related]
19. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825 [TBL] [Abstract][Full Text] [Related]
20. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]